AMI-4EUROPE Presentation Brussels

12
FP7-REGIONS-2010-1  AMI-4EUROPE  Advanced, Cross-Disciplina ry & Integrated  Medical I maging  for all EU ropeans through a Network of Regional Clusters and DevelOP ment StratE  gies 

Transcript of AMI-4EUROPE Presentation Brussels

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 1/12

FP7-REGIONS-2010-1

 AMI-4EUROPE 

 Advanced, Cross-Disciplinary &

Integrated  Medical I maging  for all

EU ropeans through a Network of 

Regional Clusters and DevelOP ment

StratE  gies 

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 2/12

FP7-REGIONS-2010-1

AMI-4EUROPE: at a glance (1)

“Next   Generation”  of Medical Imaging is just here out of the integration and cross-disciplinary use of NanoMedicine, Pharma-cological breakthroughs, Biotechnologies for healthcare and ICT combined with standard 

Medical Imaging evolution.Healthcare sector is quite diverse and collaboration has been difficult as a result, sothe challenge is to build expertise in the

development of integrated systems that address unmet clinical needs while providing asolid and consistent network of R&D +Innovation groups.

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 3/12

FP7-REGIONS-2010-1

AMI-4EUROPE: at a glance (1)

 AMI-4EUROPE is to co-ordinate, integrateand set up a newly defined EU-based Value Chain on Advanced, Cross-disciplinary and Integrated Medical Imaging by taking full 

advantage of all strengths that Europeanstakeholders have while targeting the market niches that are arising as the Next GenerationMedical Imaging unfolds itself 

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 4/12

FP7-REGIONS-2010-1

AMI-4EUROPE:  MEDICAL IMAGING RESEARCH AGENDAS 

Cross-Disciplinary Integrated Medical Imaging :

 – CLOUD MEDICAL IMAGING

– NANOTECHNOLOGIES, BIOMATERIALS AND THE USE OF

STEM CELLS AND TISSUE FOR CARDIOVASCULAR

DIAGNOSIS & TREATMENT

– ICT & IMAGING FOR ONCOLOGICAL DIFFERENTIAL

DIAGNOSIS

– NANOSCALE PHOTONIC IMAGING– PRODUCTION OF NEW MOLECULES AND RESEARCH OF

NEW MARKERS OF BIOLOGICAL PROCESSES 

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 5/12

FP7-REGIONS-2010-1

AMI-4EUROPE: KEY VALUE-ADDED ISSUES 

Regions with former experience oneconomic development throughhealth-related economy

• Strong technical expertise in the field

• Covering all major EU-27 areas +WBC + INCO

• Triple Helix in all regions + RDAsinvolved

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 6/12

FP7-REGIONS-2010-1

AMI-4EUROPE: GEOGRAPHICAL COVERAGE  

+ Africa and LatinAmerica

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 7/12

FP7-REGIONS-2010-1

AMI-4EUROPE:  MEDICAL IMAGING CURRENT EXPERTISE  

Projects with socio-economic impactalready started by partners: 

– CITE-C (Madrid)

– NANOCARDIO (Madrid)– USE OF STEM CELLS AND TISSUE FOR CARDIO-

VASCULAR DIAGNOSIS & TREATMENT (Hannover)

– ICT & IMAGING FOR ONCOLOGICAL DIFFERENTIAL

DIAGNOSIS (Hannover)

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 8/12

FP7-REGIONS-2010-1

AMI-4EUROPE: IMPACT & EXIT STRATEGY (1) 

• An enabler for public (funding agencies) and private

enterprises to enter (on a sound information basis) intothe emerging field of Advanced Medical Imaging (AMI).

• Operationally geared to make Coordinating Action

most valuable to the stakeholders in the field.

• Business opportunities related to the wider field of 

economic growth in a global context. A business plan 

(WP 6) and private-public funding (WP 2) issues are

part of the project activities.

• A European and transnational level analysis will

leverage the conclusions to the European level.

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 9/12

FP7-REGIONS-2010-1

AMI-4EUROPE: IMPACT & EXIT STRATEGY (2) 

• A knowledge transfer from 5 regional RDC to two

newly founded RDC (by coaching them and enabling )is conceived, thus creating new business

opportunities.

• Strong analysis of potential and anticipated impact in

the fields of regional up to international business opportunities are considered.

• Impact on policy making (lead markets, Pro Inno

initiative, EIT) is considered.

• The impact is aligned with the EU Commisions CIP

programm and with the ETP Nanomedecine initiative.

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 10/12

FP7-REGIONS-2010-1

AMI-4EUROPE: IMPACT & EXIT STRATEGY (3) 

• A Business Plan in support of JAP and the overall AMI

strategy is to be defined, thus assuring maximumsynergy searching and mid and long-term sustaina-

bility.

• To integrate and coordinate outcomes and results 

within the Europe INNOVA, PRO INNO Europe® andthe ETPs, to maximize synergies.

• AMI-TP Platform, AMI BackOffice, AMI DataWarehouse,

AMI Advisory Council and European Cluster for AMI are

to outlast the Project.

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 11/12

FP7-REGIONS-2010-1

AMI-4EUROPE: NEGOTIATION PHASE (1) 

• Draft versions of DoW, budget breakdown, legal andfinancial data have been submitted and are in theprocess to be finalized.

• Budget adjustments have been made as per

indications received in Negotiation Mandate:– 60% flat rates down to 20%

– Detailed breakdowns by WP and activities provided

– Total requested funding reduced to the maximum amountindicated by the EC

• Project is comprehensive, challenging and broader in

scope. Thus, further budget reduction will result in loss

of outcomes and results.

8/3/2019 AMI-4EUROPE Presentation Brussels

http://slidepdf.com/reader/full/ami-4europe-presentation-brussels 12/12

FP7-REGIONS-2010-1

AMI-4EUROPE: NEGOTIATION PHASE (2) 

• OPEN ISSUES.

– Treatment of organizations participating under the“umbrella” of the Clusters

• Beneficiaries vs. Third Parties vs. Consultants

–Agreement on submitted budget and DoW

– Ways to proceed to “clear” pending legal issues with somebeneficiaries

– Consortium Agreement

– Tentative starting date

• ISSUES TO BE RAISED BY THE EC (if any).